Moleculin Biotech, INC 8-K filings

Moleculin Biotech announces a new collaboration with CIC biomaGUNE to conduct investigator-initiated preclinical research on Annamycin for glioblastoma multiforme, a severe form of brain cancer.

Moleculin Biotech, Inc. will implement a 1-for-25 reverse stock split effective December 1, 2025, to consolidate shares and maintain its Nasdaq listing.

Moleculin Biotech, Inc. announced the posting of its latest corporate investor presentation on its company website.

Moleculin Biotech, Inc. received a delist determination from Nasdaq for failing to meet minimum stockholders' equity requirements but plans to appeal.

Moleculin Biotech announced 60% enrollment for the first interim unblinding of its pivotal Phase 2B/3 MIRACLE study of Annamycin for relapsed/refractory AML, with initial data expected in Q1 2026.

Moleculin Biotech, Inc. announced a research agreement with the University of North Carolina at Chapel Hill to evaluate Annamycin for pancreatic cancer treatment.

Moleculin Biotech, Inc. announced it has posted its updated corporate investor presentation on its website.

Moleculin Biotech announced the grant of an Australian patent for its Annamycin drug candidate, enhancing its global intellectual property portfolio.

Moleculin Biotech announced a new investigator-initiated Phase 1B/2 study of Annamycin for third-line advanced pancreatic cancer with Atlantic Health.

Moleculin Biotech, Inc. stockholders approved the issuance of shares for warrants but did not approve a corporate name change at a recent Special Meeting.

Moleculin Biotech, Inc. announced a notice of allowance for a Canadian patent covering its Annamycin drug candidate, strengthening its global intellectual property portfolio.

Moleculin Biotech announced accelerated recruitment and global expansion for its pivotal Phase 3 MIRACLE clinical trial of Annamycin for relapsed or refractory acute myeloid leukemia.

Moleculin Biotech, Inc. announced the posting of its latest corporate investor presentation on its company website.

Moleculin Biotech announced the enrollment of the first two subjects and treatment of one in the EU for its pivotal Phase 2B/3 MIRACLE trial for relapsed or refractory Acute Myeloid Leukemia (R/R AML).

Moleculin Biotech secured approximately $6.0 million in gross proceeds by inducing existing warrant holders to exercise their warrants, issuing new Series F warrants in return.

Moleculin Biotech increased authorized common stock and announced positive overall survival data from its Phase 1B/2 Annamycin AML clinical trial.

Moleculin Biotech, Inc. has filed an 8-K to furnish its latest corporate investor presentation, available on its website.

Moleculin Biotech, Inc. stockholders approved director elections, auditor ratification, executive compensation, and significant share authorizations for warrants and future capital needs, while rejecting a supermajority voting change.

Moleculin Biotech, Inc. announced its second quarter 2025 financial results, highlighting significant progress in its MIRACLE trial for AML and positive topline data for Annamycin in STS lung metastases, while facing increased net loss and a short cash runway.

Moleculin Biotech announces encouraging preclinical data for Annamycin demonstrating significant efficacy against various primary and metastatic liver cancers.

Moleculin Biotech, Inc. announced it is furnishing its July 2025 Investor Presentation as an exhibit to its latest 8-K filing.

Moleculin Biotech, Inc. announced receipt of a Notice of Intent to Grant a new European patent for its drug candidate Annamycin, enhancing its intellectual property portfolio and market position.

A late-stage pharmaceutical company has appointed a seasoned industry veteran as a Strategic Advisor to accelerate partnerships, particularly ahead of key clinical trial data unblinding for its lead cancer drug.

Moleculin Biotech, Inc. has entered into an At The Market Offering Agreement with Roth Capital Partners, LLC to sell up to $6.5 million of its common stock for working capital and general corporate purposes.

Moleculin Biotech, Inc. announced the approval of its pivotal Phase 2B/3 MIRACLE clinical trial for Annamycin in relapsed/refractory Acute Myeloid Leukemia in Georgia, alongside an update on enrollment and future site expansion plans.

Moleculin Biotech, Inc. has received a deficiency letter from Nasdaq for failing to maintain a minimum bid price of $1.00 per share, initiating a 180-day compliance period.

Moleculin Biotech, Inc. has successfully priced a public offering, raising approximately $5.9 million in gross proceeds to advance its clinical and preclinical drug development programs.

Moleculin Biotech, Inc. announced positive feedback from the FDA on its Initial Pediatric Study Plan for Annamycin, allowing for a single pediatric approval study in children as young as 6 months with relapsed/refractory acute myeloid leukemia.

Moleculin Biotech, Inc. announced it hosted a virtual Key Opinion Leader (KOL) event on June 5, 2025, focusing on Soft Tissue Sarcoma (STS) Lung Metastases.

Moleculin Biotech, Inc. announced positive topline efficacy results from its completed U.S. Phase 1B/2 clinical trial (MB-107) evaluating Annamycin for the treatment of soft tissue sarcoma lung metastases, demonstrating promising survival rates and no cardiotoxicity.